Kabasure Kudineer 对比维生素 C 与锌治疗无症状 COVID-19 的随机对照试验方案
本研究为单中心、开放标签、平行组、探索性随机对照试验,计划纳入 60 例 RT-PCR 阳性无症状 COVID-19 患者,按 1:1 随机分配至 Kabasure Kudineer(KSK)组或维生素 C 与锌(CZ)组,治疗 14 天。主要目的是比较 KSK 与 CZ 在降低 SARS-CoV-2 病毒载量、预防无症状转为有症状以及免疫标志物变化方面的疗效,并评估安全性。
要点
- KSK 组口服 KSK 煎剂 60ml,每日早晚各一次,餐后服用,共 14 天。
- 对照组口服维生素 C 60000 IU 和锌 100mg,每日早晚各一次,共 14 天。
- 主要结局包括第 7 天 RT-PCR CT 值较基线的变化、症状进展及免疫标志物变化。
核心结论
- 该研究为探索性试验方案,旨在评估 KSK 对比 CZ 在无症状 COVID-19 中的疗效与安全性。
研究设计与样本
- 单中心、开放标签、平行组(1:1 分配)、探索性随机对照试验。
- 计划招募 60 例参与者,每组 30 例,采用 Microsoft Excel 随机数生成和密封信封分配。
- 纳入标准为 RT-PCR 阳性、年龄 18 至 55 岁、无症状且无糖尿病、高血压和支气管哮喘等合并症。
主要发现
- 主要结局为第 7 天 RT-PCR CT 值较基线的变化、预防无症状转为有症状(发热、咳嗽、气短)及免疫标志物变化。
- 免疫标志物包括白介素 6、白介素 10、白介素 2、干扰素 γ 和肿瘤坏死因子 α。
- 次要结局为按 Siddha 医学原则的临床评估和不良事件发生情况。
关键数值与推荐
- KSK 组:5g KSK 粉末加 240ml 水煮沸浓缩至 60ml,过滤后口服 60ml,每日早晚各一次,餐后服用,共 14 天。
- 对照组:口服维生素 C 60000 IU 和锌 100mg,每日早晚各一次,共 14 天。
- 排除标准包括妊娠或哺乳期、严重呼吸系统疾病、正在参与其他 COVID 试验以及恶性肿瘤等严重疾病。
临床怎么用
- 该方案为探索性试验,结果尚未报告,暂不能指导临床实践。
局限性
- 因无既往 KSK 试验数据,样本量无法计算,本研究为 pilot 试验,计划招募 60 例。
- 研究为开放标签设计,但数据分析由未参与试验的统计师进行盲法分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The primary objectives of this study are to determine efficacy of Siddha medicine, Kabasura kudineer in reduction of SARS-CoV-2 viral load and reducing the onset of symptoms in asymptomatic COVID-19 when compared to Vitamin C and Zinc (CZ) supplementation. In addition, the trial will examine the changes in the immunological markers of the Siddha medicine against control. The secondary objectives of the trial are to evaluate the safety of the Siddha medicine and to document clinical profile of asymptomatic COVID-19 as per principles of Siddha system of Medicine. TRIAL DESIGN: A single centre, open-label, parallel group (1:1 allocation ratio), exploratory randomized controlled trial. PARTICIPANTS: Cases admitted at non-hospital settings designated as COVID Care Centre and managed by the State Government Stanley Medical College, Chennai, Tamil Nadu, India will be recruited. Eligible participants will be those tested positive for COVID-19 by Reverse Transcriptase Polymerase Chain reaction (RT-PCR) aged 18 to 55 years without any symptoms and co-morbidities like diabetes mellitus, hypertension and bronchial asthma. Those pregnant or lactating, with severe respiratory disease, already participating in COVID trials and with severe illness like malignancy will be excluded. INTERVENTION AND COMPARATOR: Adopting traditional methods, decoction of Kabasura kudineer will be prepared by boiling 5g of KSK powder in 240 ml water and reduced to one-fourth (60ml) and filtered. The KSK group will receive a dose of 60ml decoction, orally in the morning and evening after food for 14 days. The control group will receive Vitamin C (60000 IU) and Zinc tablets (100mg) orally in the morning and evening respectively for 14 days. MAIN OUTCOMES: The primary outcomes are the reduction in the SARS-CoV-2 load [as measured by cyclic threshold (CT) value of RT-PCR] from the baseline to that of seventh day of the treatment, prevention of progression of asymptomatic to symptomatic state (clinical symptoms like fever, cough and breathlessness) and changes in the immunity markers [Interleukins (IL) 6, IL10, IL2, Interferon gamma (IFNγ) and Tumor Necrosis Factor (TNF) alpha]. Clinical assessment of COVID-19 as per standard Siddha system of medicine principles and the occurrence of adverse effects will be documented as secondary outcomes. RANDOMISATION: The assignment to the study or control group will be allocated in equal numbers through randomization using random number generation in Microsoft Excel by a statistician who is not involved in the trial. The allocation scheme will be made by an independent statistician using a sealed envelope. The participants will be allocated immediately after the eligibility assessment and informed consent procedures. BLINDING (MASKING): This study is unblinded. The investigators will be blinded to data analysis, which will be carried out by a statistician who is not involved in the trial. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Sample size could not be calculated, as there is no prior trial on KSK. This trial will be a pilot trial. Hence, we intend to recruit 60 participants in total using a 1:1 allocation ratio, with 30 participants randomised into each arm. TRIAL STATUS: Protocol version 2.0 dated 16th May 2020. Recruitment is completed. The trial started recruitment on the 25th May 2020. We anticipate study including data analysis will finish on November 2020. We also stated that protocol was submitted before the end of data collection TRIAL REGISTRATION: The study protocol was registered with clinical trial registry of India (CTRI) with CTRI/2020/05/025215 on 16 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
引用
- Natarajan S, Anbarasi C, Sathiyarajeswaran P, et al. The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33109252. doi:10.1186/s13063-020-04823-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。